Moleculin Biotech Inc. (MBRX)
NASDAQ: MBRX
· Real-Time Price · USD
0.53
0.00 (0.00%)
At close: Oct 01, 2025, 1:46 PM
0.00% (1D)
| Bid | 0.38 |
| Market Cap | 16.17M |
| Revenue (ttm) | 126K |
| Net Income (ttm) | -26.55M |
| EPS (ttm) | -3.7 |
| PE Ratio (ttm) | -0.14 |
| Forward PE | -0.54 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 0.68 |
| Volume | 2,428,608 |
| Avg. Volume (20D) | 5,596,876 |
| Open | 0.54 |
| Previous Close | 0.53 |
| Day's Range | 0.52 - 0.55 |
| 52-Week Range | 0.25 - 3.65 |
| Beta | 1.50 |
| Ex-Dividend Date | n/a |
About MBRX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol MBRX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for MBRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
+11.33%
MBRX stock has given up its prior gain. Moleculin ...
Unlock content with
Pro Subscription
1 month ago
+11.33%
Moleculin Biotech shares are trading higher after the company announced the completion of its Phase 1B/2 clinical trial evaluating Annamycin in combination with Cytarabine for the treatment of subjects with acute myeloid leukemia
